Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs.

Food Chem Toxicol

Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, University of Erciyes, Kayseri, Turkey.

Published: November 2010

Little is known about the kinetics of ivermectin formulations following subcutaneous administration in dogs. The vehicle components used in production may change the pharmacokinetics of the drug. The present study was aimed at the comparison of the pharmacokinetics of seven injectable ivermectin formulation of different brand names (A-G). The animals were allocated to seven groups, each comprising seven dogs. The dogs were administered ivermectin at a dose of 200 microg/kg bw by subcutaneous route and blood samples were collected from all groups up to 288h post-injection. Plasma ivermectin analyses were performed using a HPLC with a fluorescence detector. Compared to Group 1(A), it was determined that statistically significant differences existed in Groups 2(B), 3(C), 4(D), 5(E), and 7(G) for C(max) values; and in Groups 3(C), 4(D), 6(F), 7(G) for AUC(0-->288) and AUC(0-->infinity) values. These values were highest in Group 1(A) and lowest in Group 7(F). The results obtained in the present study demonstrated that, in cases which require subacute administration, optimal exposure is achieved with the preparation A. However, it must be noted that this evaluation was based on pharmacokinetic parameters and not antiparasitic efficacy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2010.05.043DOI Listing

Publication Analysis

Top Keywords

pharmacokinetics injectable
8
ivermectin
5
comparative pharmacokinetics
4
injectable preparations
4
preparations ivermectin
4
dogs
4
ivermectin dogs
4
dogs kinetics
4
kinetics ivermectin
4
ivermectin formulations
4

Similar Publications

Introduction: 7,8-Dihydroxyflavone (7,8-DHF) is a promising translational therapy in several brain injury models, including the neonatal hypoxia-ischemia (HI) model in mice. However, the neuroprotective effect of 7,8-DHF was only observed in female, but not male, neonatal mice with HI brain injury. It is unknown whether HI-induced physiological changes affect brain distribution of 7,8-DHF differently for male versus female mice.

View Article and Find Full Text PDF

Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.

View Article and Find Full Text PDF

PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.

View Article and Find Full Text PDF
Article Synopsis
  • CAB + RPV is the first long-acting HIV treatment regimen using thigh injections, showing promising results in maintaining viral suppression.
  • The study involved 118 participants and compared pharmacokinetic changes and tolerability between thigh and gluteal injections, finding no significant differences in effectiveness.
  • Results indicated that a majority of participants preferred thigh injections, with potential plans for more flexible dosing schedules to enhance treatment convenience.
View Article and Find Full Text PDF
Article Synopsis
  • The study compared the bioavailability of the anti-interleukin-5 antibody depemokimab when delivered using a safety syringe device (SSD) versus an autoinjector (AI) in healthy adults.
  • Both methods showed similar plasma concentration profiles and pharmacokinetic parameters, confirming that they are bioequivalent.
  • Adverse events were minor and comparable between the two delivery methods, with headaches being the most common side effect, indicating both devices are safe for administering depemokimab.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!